K. Sall

发表

Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial

M. Korenfeld, S. Robertson, J. Stein, 2021, Eye.

Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies

K. Sall, E. Meier, A. Narvekar, 2017, Clinical ophthalmology.

Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.

B. Reis, K. Sall, T. Mundorf, 2000, Ophthalmology.

Diquafosol Tetrasodium (INS365) Ophthalmic Solution is Not Absorbed Systemically in Patients with Dry Eye

D. Kellerman, R. Whitsell, K. Sall, 2003 .

Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

R. DeFronzo, D. Kendall, J. Gross, 2006, Diabetes Care.

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma

J. Myers, K. Sall, R. Baumgartner, 2016, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma.

W. C. Stewart, K. Singh, L. Katz, 1999, American journal of ophthalmology.

An Evaluation of the Efficacy of a Cyclosporine-Based Dry Eye Therapy When Used With Marketed Artificial Tears as Supportive Therapy in Dry Eye

Stephen Cohen, J. Stein, K. Sall, 2006, Eye & contact lens.

Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials

S. Lane, E. Holland, K. Sall, 2016, Current medical research and opinion.

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-compa

R. DeFronzo, D. Kendall, J. Gross, 2006, Diabetes care.

Absorption of Topical Moxifloxacin Ophthalmic Solution Into Human Aqueous Humor

S. Masket, S. Lane, D. Dahlin, 2005, Cornea.

The Efficacy and Safety of Brinzolamide 1% Ophthalmic Suspension (Azopt®) as a Primary Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

K. Sall, 2000 .

Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy

Rishi P. Singh, G. Jaffe, K. Sall, 2012, Clinical ophthalmology.

Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).

Mitchell A Jackson, E. Holland, K. Nichols, 2017, Ophthalmology.

Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease1

B. Reis, K. Sall, T. Mundorf, 2000 .

Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.

Christopher S. Foster, James T. Rosenbaum, M. Raizman, 1999, American journal of ophthalmology.

Evaluation of clinical outcomes in patients with dry eye disease using lubricant eye drops containing polyethylene glycol or carboxymethylcellulose

Stephen Cohen, K. Sall, Anna Martin, 2013, Clinical ophthalmology.

Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients.

S. Lane, R. Lindstrom, R. Faulkner, 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Report of an incarcerated Lynell anterior chamber intraocular lens

K. Sall, R. H. Keates, J. K. Kreter, 1986, Journal of cataract and refractive surgery.

Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery

Terry Kim, Preeya K Gupta, E. Holland, 2018, Clinical ophthalmology.

EFFICACY AND SAFETY OF CYCLOSPORINE OPHTHALMIC EMULSION IN DRY EYE DISEASE

K. Sall, T. Mundorf, O. D. Stevenson, 2000 .

Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of LUMIGAN or TRAVATAN.

N. Sharif, D. Dahlin, J. Whitson, 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies.

K. Nichols, G. Foulks, M. Korenfeld, 2020, Cornea.

Long-term Safety and Efficacy of a Sustained-Release Bimatoprost Ocular Ring.

J. Brandt, K. Sall, C. Semba, 2017, Ophthalmology.

Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study.

J. Brandt, K. Sall, C. Semba, 2016, Ophthalmology.

Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.

J. Samples, K. Sall, H. Dubiner, 2013, JAMA ophthalmology.

Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.

P. Karpecki, K. Sall, J. Tauber, 2015, Ophthalmology.

The Safety and Efficacy of Bimatoprost/Timolol Fixed Combination: A 1-year Double-masked, Randomized Parallel Comparison to Its Individual Components in Patients With Glaucoma or Ocular Hypertension

R. Lewis, R. Gross, R. Schiffman, 2010, Journal of glaucoma.